Search results

The purpose of this paper is to investigate the challenges faced by empirical researchers investigating a shift from taxing multinational entities using the arm’s length system to a formulary apportionment system. Theoretically, a shift should increase global tax collections as profits currently attributed to low or no tax jurisdictions are allocated to jurisdictions with true input or output factors and shift the allocation between these countries. Before any jurisdiction seriously contemplated a shift from an arm’s length allocation system to a formulary apportionment regime, however, it would want to estimate the revenue impact of such a change.

The paper systematically analyzes empirical papers that attempt to estimate the effects of formulary apportionment on country and global income revenue collected to determine the challenges faced by researchers.

The paper determines that there are both data and geo-political constraints that relate to (1) the method used to calculate the global profits of a multinational enterprise, (2) whether jurisdictions wish to adopt a global or regional formulary apportionment, (3) the weightings to be given to the factors used in the formulary apportionment, (4) the challenges of measuring sales at destination and the viability of surrogate measurements, (5) whether natural resources should be included in the measurement of the capital input factor, and (6) whether a redistribution objective should be included in the profit allocation formula.

Estimating the changes is challenging both in terms collecting the data needed for the calculations and the choice of design options to be tested. The paper provides synthesized knowledge in relation to the difficulties in estimating the effects of moving to a formulary apportionment model for taxing multinational entities.

Rapid innovation and developments in personal electronic technology have encouraged users to change users' devices more frequently than ever, which has resulted in creating a massive increase in the amount of electronic waste. The study focuses on identifying the barriers to closed-loop supply chain (CLSC) in the electronic industry.

A framework for analyzing the relationships among CLSC adoption barriers is designed. The authors adopted the decision-making trial and evaluation laboratory (DEMATEL) technique to determine the critical barriers of electronic CLSC from the opinion of experts in the field.

The outcome from the analysis suggests that cost barriers, financial barrier, process barriers and supplier-side barriers are the main causal factors that prevent the adoption and implementation of e-waste CLSC. The causal relationship indicates that financial barrier is the most influential factor, while phycological barrier is the most flexible barrier to the adoption of e-waste CLSC.

This study is restricted to CLSC adoption barriers in the electronic industry by evaluating 36 sub-barriers grouped into 8 main dimensions related to different members of the supply chain.

Closed-loop adoption barriers have been proposed to understand the crucial barriers to implementation of CLSC in the electronic industry. The cause-and-effect relationship indicates the critical factors to be improved to increase adoption of e-waste CLSC, helping managers and regulatory bodies to mitigate the problem areas.

This study contributes to the literature on CLSC by adopting a multi-criteria decision-making (MCDM) technique which captures the critical barriers of e-waste CLSC adoption in Indian scenario.

This review paper delves into the comprehensive understanding of Ashwagandha, spanning its botanic occurrence, conventional applications, extraction techniques and pivotal role in addressing various disorders.

Introduction Ashwagandha, also known as Withania somnifera, is a remarkable botanical resource with a rich history of use in traditional medicine.

In botany, Withania somnifera thrives in diverse ecosystems, particularly in tropical and subtropical regions. Its extensive distribution across regions, the Canary Islands, South Africa, the Middle East, Sri Lanka, India and China underscores its adaptability and resilience. The traditional uses of Ashwagandha in Ayurvedic and indigenous medicine systems have persisted for over 3,000 years. With over 6,000 plant species utilized historically, India, often regarded as the “botanical garden of the world,” has firmly established Ashwagandha as a cornerstone in traditional healing practices.

Extraction methods play a pivotal role in harnessing the therapeutic potential of Ashwagandha. Ultrasonic-assisted extraction and high-performance liquid chromatography are among the techniques employed to obtain the key bioactive compounds. Ashwagandha’s significance in modern medicine is underscored by its potential to address a spectrum of health issues. The multifaceted bioactivity of Ashwagandha is attributed to its antioxidant, anti-inflammatory, heart conditions, metabolic disorders, renal ailments, hepatic diseases and adaptogenic properties, making it a subject of increasing interest in contemporary medical research. This review synthesizes the assorted perspectives of Ashwagandha, from its botanical roots and conventional employments to its advanced extraction strategies and its intention to basic well-being challenges, advertising important bits of knowledge for analysts, specialists and healthcare experts alike.